0408 Insomnia Severity Differences by Psilocybin, LSD, and DMT Use Status Among Young Adult Daily Cannabis Consumers in the Herbal Heart Study
SLEEP May 1, 2026 Denise Vidot, Bria-Necole Diggs, Amrit Baral et al.
Among daily cannabis consumers aged 18–35, about 56% reported lifetime psychedelic use, with psilocybin most common (50%), followed by LSD (29%) and DMT (3.5%). Overall, 33% had subthreshold insomnia, 3.2% moderate-severity clinical insomnia, and 1.6% severe clinical insomnia. LSD and DMT were associated with moderate-to-severe clinical insomnia: 17.7% of LSD users vs. 0.0% of non-users, and 50.0% of DMT users vs. 3.6% of non-users. Psilocybin showed no significant association. LSD users also reported more frequent sleep-related interference with daily functioning. No differences were found in cannabis use for sleep or demographics by psychedelic use.